Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Josefina Cruz Jurado"'
Autor:
Encarnación González Flores, Alicia Quílez Cutillas, Alejandro González, Salvador Gámez Casado, Marta Amérigo Góngora, Javier Salvador Bofill, Maria Carmen Álamo de la Gala, Carlos José Rodríguez González, Josefina Cruz Jurado, Pedro Sánchez Rovira, Rocío Urbano Cubero, Rocío Álvarez Ambite, Elisenda Llabrés Valenti, Maria Valero Arbizu, Fernando Henao Carrasco, Manuel Ruiz Borrego, Antonia Martínez Guisado
Publikováno v:
Cancer Research. 80:P1-18
Background: Pertuzumab (P) has been aproved in neoadjuvant setting for HER2 positive early breasta cancer patients in association with Trastuzumab (T) and chemotherapy. Diverse studies support this combination as NeoSphere, Tryphaena, GeparSepto or B
Autor:
Rosalia Caballero, Maribel Casas, Fernando Moreno, Massimo Chiesa, Natalia Palazón-Carrión, María Gion, Manuel Ramos, Javier Cortes, Josefina Cruz-Jurado, Isaac Ceballos, Raquel Andrés, Víctor Sánchez-Margalet, Jose L Alonso-Romero, Luis de la Cruz-Merino, Federico Rojo, Fernando Henao-Carrasco, Luz Milva Rodriguez Rodriguez, Elena López-Miranda, Esther Holgado, Vanesa Quiroga, Susana Bezares, Sara Benito, Carlos Jiménez-Cortegana
Publikováno v:
Scientia
Cancers
Volume 13
Issue 21
Cancers, Vol 13, Iss 5432, p 5432 (2021)
Cancers
Volume 13
Issue 21
Cancers, Vol 13, Iss 5432, p 5432 (2021)
The PANGEA-Breast trial evaluated a new chemo-immunotherapeutic combination that would synergistically induce long-term clinical benefit in HER2-negative advanced breast cancer patients. Treatment consisted of 21-day cycles of 200 mg of pembrolizumab
Autor:
Josefina Cruz Jurado, Daniel Bernabeu, Claudia M Valverde-Morales, Andrés Redondo, Javier Lavernia, Javier Martin-Broto, Javier Martinez-Trufero, Cristina Mata, Gloria Marquina, Ana Sebio, Raquel Correa, Rosa Alvarez, Jose Manuel Asencio, Luis Javier Floría, C Nieves Hernández-León, Nadia Hindi, M Carmen Gómez-Mateo, Xavier Garcia del Muro, Virginia Martínez
Publikováno v:
Cancer treatment reviews. 99
Among all Soft Tissue sarcomas there are some subtypes with low incidence and/or peculiar clinical behaviour, that need to be consider separately. Most of them are orphan diseases, whose biological characteristics imply a clearly different diagnostic
Autor:
Javier Martinez-Trufero, Jose Manuel Asencio, Javier Martin-Broto, Nadia Hindi, Rosa Alvarez, Javier Lavernia, Andrés Redondo, Cristina Mata, Josefina Cruz Jurado, Raquel Correa, Ana Sebio, Gloria Marquina, Daniel Bernabeu, Claudia Maria Valverde Morales, Luis Javier Floría, C Nieves Hernández-León, Virginia Martínez, Xavier Garcia del Muro, M Carmen Gómez-Mateo
Publikováno v:
Cancer treatment reviews. 99
Autor:
Roberto Diaz-Beveridge, Luis Miguel De Sande-González, Antonio López Pousa, Jordi Rubió-Casadevall, Javier Martin-Broto, Pablo Luna, Juan Antonio Carrasco, Claudia M Valverde-Morales, Andres Poveda, Gloria Marquina, María Ángeles Vaz Salgado, Javier Martinez-Trufero, Antonio Gutierrez, Ana De Juan, Juana María Cano, Ibon Gurruchaga-Sotes, Isabel Sevilla, Josefina Cruz-Jurado, Jerónimo Martínez-García, Rosa Alvarez, David S. Moura
Publikováno v:
Cancers
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Cancers, Vol 13, Iss 792, p 792 (2021)
Scientia
Volume 13
Issue 4
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Cancers, Vol 13, Iss 792, p 792 (2021)
Scientia
Volume 13
Issue 4
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
The aim of this study was to identify an easily reliable prognostic score that selects the subset of advanced soft tissue sarcoma (ASTS) patients with a higher benefit with trabectedin in terms of time to progression and overall survival. A retrospec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7ae189020c1b9820dc01b3e6d0041c2
https://hdl.handle.net/10668/17307
https://hdl.handle.net/10668/17307
Autor:
Matías Llabres Martinez, José Norberto Batista López, Marta Llanos Muñoz, Ruth Ramos Díaz, Isaac Ceballos Lenza, Josefina Cruz Jurado, Alejandro Jiménez Sosa, María Micaela Viña Romero, Fernando Gutiérrez Nicolás, Gloria Julia Nazco Casariego, Jonathan González García
Publikováno v:
The Annals of pharmacotherapy. 54(8)
Background: Subcutaneous trastuzumab (T-SC) administration does not allow the historical target concentration of 20 µg/mL for efficacy to be reached, from the start of treatment in patients with a body mass index (BMI) >30 kg/m2. Objectives: To anal
Autor:
Rosa Alvarez, Josefina Cruz Jurado, Xavier García Del Muro Solans, Claudia Valverde, Javier Martin-Broto, Antonio López Pousa, Javier Lavernia Giner
Publikováno v:
Sarcoma
Scientia
Sarcoma, Vol 2019 (2019)
Scientia
Sarcoma, Vol 2019 (2019)
Delphi consensus; Sarcoma treatment; Panel of experts Consenso Delphi; Tratamiento del sarcoma; Panel de expertos Consens Delphi; Tractament del sarcoma; Panell d'experts Soft tissue sarcomas (STS) constitute a heterogeneous group of rare solid tumor
Autor:
Beatriz Suarez-Paniagua, Andrés Redondo, Josefina Cruz Jurado, Claudia Valverde, Cleofé Romagosa, Martina Giuppi, Virginia Martínez, Javier Martinez-Trufero, Xavier Guri, César Serrano
Publikováno v:
Journal of Clinical Oncology. 39:11534-11534
11534 Background: KIT or PDGFRA oncogenic activation drives GIST progression throughout the disease course. Accordingly, currently approved agents in metastatic GIST focus on the therapeutic suppression of these receptors. However, the clinical benef
Autor:
José Antonio López-Guerrero, Emanuela Palmerini, Samuel Hidalgo, Jean-Yves Blay, Antonio Lopez-Pousa, Ana Sebio, Antoine Italiano, Silvia Stacchiotti, Antonio Gutierrez, Paolo G. Casali, David S. Moura, Javier Martinez-Trufero, Josefina Cruz Jurado, Daniel Bernabeu, Javier Martin Broto, Giovanni Grignani, Xavier Garcia del Muro, Andrés Redondo, Axel Le Cesne, Nadia Hindi
Publikováno v:
Journal of Clinical Oncology. 39:11511-11511
11511 Background: Pazopanib (P) was assessed prospectively in a phase 2 study in SFT resulting in a longer progression free survival (PFS) and overall survival (OS) compared to historical controls treated with chemotherapy. No statistical correlation
Autor:
Yen-Shen Lu, Udaiveer Panwar, Marianne Leheurteur, Johan Ahlgren, Dragana Jankovic, H. Hu, Fabrice Andre, Hope S. Rugo, Xueying Chen, Howard A. Burris, Dejan Juric, Zsuzsanna Papai, Ines Lorenzo, Cornelia Quadt, Josep Tabernero, Salomon M. Stemmer, Josefina Cruz Jurado, Filip Janku
Publikováno v:
Journal of Clinical Oncology. 39:1054-1054
1054 Background: PIK3CA mutations, present in ̃40% of HR+, HER2– ABC, are associated with therapeutic resistance and shorter survival. Alpelisib (ALP) + fulvestrant (FUL) demonstrated efficacy in this population for which achieving long-term (LT)